ReviewWomen's health nursing (Seoul, Korea)2026
Clinical evaluation and treatment of obesity in women across selected life stages: a narrative review.
Review in Women's health nursing (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was performed to synthesize current evidence on evaluating and treating obesity in women across selected life stages relevant to women's health nursing practice.
methodsFor this invited narrative review, targeted searches of PubMed and guideline and regulatory sources available through July 2026 identified current diagnostic and staging frameworks, Korean and international guidance, pharmacotherapy evidence, official prescribing information, and literature on reproductive and menopausal physiology for synthesis. Sources were selected purposively rather than systematically.
resultsThe Lancet criteria for clinical obesity, the Edmonton Obesity Staging System, and a four-domain assessment of mechanical, metabolic, mental, and social milieu factors offer complementary ways to confirm adiposity, diagnose illness, stage severity, and assess health beyond body mass index. Medication selection should be based primarily on approved indications, efficacy, safety, comorbidities, reproductive plans, access, and patient preferences; phenotype-guided matching remains investigational. Care for women of reproductive age should address polycystic ovary syndrome, pregnancy intention, and the oral hormonal contraceptive precautions specific to tirzepatide. During pregnancy and lactation, appropriate weight trajectories and medication safety for the individual agent take precedence over pharmacologic weight loss. Declining estradiol during the menopausal transition is associated with central fat redistribution, while lean mass loss also reflects aging; an independent effect of follicle-stimulating hormone remains unestablished. Menopausal hormone therapy should be prescribed for established menopausal indications rather than for weight loss.
conclusionObesity care for women should integrate disease-based assessment, individualized treatment supported by evidence, medication counseling tailored to life stage, nonstigmatizing communication, and shared decision-making. Nurses should support assessment, education, monitoring, and coordination within their scope of practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.